More To FDA AdComm Selection Process Than Meets The Eye
This article was originally published in The Gray Sheet
Executive Summary
FDA issued a draft guidance on how it addresses "appearance issues" when it comes to reviewing conflicts of interest in prospective members of an advisory committee. The agency says the guidelines are needed due to a general lack of understanding about how FDA selects and evaluates members of its panels, and how it grants waivers to participate.
You may also be interested in...
With Five Guidances, FDA Overhauls Its Advisory Committee Policies
FDA should hold voluntary advisory committee meetings only for matters that are of significant public interest or controversy, or that demand unique expertise, the agency's Office of Policy, Planning and Preparedness says in a 1draft guidance released Aug. 5
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.
HHS Secretary Nominee Becerra Commits To Telehealth Expansion, Procedure Price Transparency
At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.